Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC Meeting Abstract
| Authors: | Han, H. S.; Kalinsky, K.; Abuhadra, N.; Giordano, A.; Starks, D.; Wulf, G. M.; McAndrew, N. P.; O'Shaughnessy, J.; Spira, A. I.; Chan, N.; Kelley, K.; Parajuli, R.; Weise, A. M.; Chaudhry, A.; Wang, J. S.; Richardson, D. L.; Roque, D. R.; Meric-Bernstam, F.; Rogalski, C.; Hamilton, E. P. |
| Abstract Title: | Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| Start Page: | TPS1141 |
| Language: | English |
| ACCESSION: | WOS:001509255600001 |
| DOI: | 10.1200/JCO.2025.43.16_suppl.TPS1141 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
